禾木生物于2020年4月起产生收益，并将首个产品TracLine®血管内通路导管商业化，且于2021年4月及7月分别将FocuStar神经球囊导管-Rx及Afentta颅内血栓抽吸导管商业化。截至2019年12月31日及2020年12月31日止财政年度及截至2021年5月31日止五个月的全部收益乃来自销售TracLine血管内通路导管及FocuStar神经球囊导管-Rx。因此，公司截至2019年12月31日及2020年12月31日止财政年度及截至2021年5月31日止五个月录得经营现金流出净值。随着公司推出额外产品提高生产量，建立销售团队，以及加强营销活动，预期公司在未来几年将增加收益，并将提升营业能力。Zitong Financial APP learned that according to the disclosure of the HKEx on July 30, Wemu Bioengineering Co., Ltd. (HeMo Bioengineering Limited) submitted an application for listing on the main board of the HKEx, with Morgan Stanley, China International Capital Corporation and Credit Suisse as co-sponsors.
Company profile
Wo Mu Bio has established a full range of innovative interventional medical devices for neurovascular and peripheral diseases in China and the Asia-Pacific region. Its comprehensive product portfolio of neurointerventional medical devices covers all areas of ischemic stroke, hemorrhagic stroke and neural pathways. The company is the pioneer of mechanical thrombectomy for acute ischemic stroke in China, and the domestic aspiration catheter Afentta, which is the first to appear on the market, can prove this point. Afentta intracranial thrombus aspiration catheter, one of the company's main products, is the first aspiration catheter approved by the State Drug Administration and commercialized in China. Other major products Model 088 HMC1- NAS intracranial thrombus aspiration catheter, once approved, may be the aspiration catheter with the largest distal internal diameter in the world among the suction catheters on the market. In addition, the company's peripheral intervention medical devices cover vascular and non-vascular intervention. The core product Privi hemorrhoid cooling balloon is a non-vascular interventional medical device that only uses physical mechanisms to treat hemorrhoids without the need for drugs or ingredients that may be associated with side effects. As of the latest practicable date, the company has three commercialized products, four additional approved products, three products under development under registration review or clinical trials, and twelve products under development in the preclinical stage.
The first product, TracLine ®Intravascular Catheter, was commercialized in April 2020, and FocuStar Neuroballoon Catheter-Rx and Afentta Intracranial Thrombus aspiration Catheter were commercialized in April and July 2021, respectively. All revenue for the financial years ended 31 December 2019 and 31 December 2020 and the five months ended 31 May 2021 came from the sale of TracLine intravascular access catheters and FocuStar nerve balloon catheters-Rx. As a result, the Company recorded net operating cash outflows for the financial years ended 31 December 2019 and 31 December 2020 and for the five months ended 31 May 2021. As the company launches additional products to increase production, set up a sales team, and strengthen marketing activities, the company is expected to increase revenue and improve operating capacity in the next few years.
financial status
According to the prospectus, as of December 31, 2020 and May 31, 2021, the income of grasses was 2.839 million yuan and 581000 yuan respectively (unit: RMB, the same below).
As of 31 December 2019, 31 December 2020 and 31 May 2021. The losses of grasses during the period were 121 million yuan, 615 million yuan and 244 million yuan respectively.
